Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
Identifieur interne : 000322 ( France/Analysis ); précédent : 000321; suivant : 000323Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
Auteurs : Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-02-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Bicyclo Compounds, Heterocyclic (therapeutic use), Clinical trial, Dopamine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, NS 2330, Nervous system diseases, Neurotransmitter Uptake Inhibitors (therapeutic use), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Retrospective Studies, Reuptake inhibitor, Tesofensine, Treatment, clinical trial, dopamine reuptake inhibitor, dopamine transporter, monotherapy, tesofensine, treatment.
- MESH :
- chemical , therapeutic use : Bicyclo Compounds, Heterocyclic, Neurotransmitter Uptake Inhibitors.
- drug therapy : Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Retrospective Studies.
Abstract
The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). In MPTP (1‐methyl 4‐phenyl‐tetrahydropyridine 1,2,3,6)‐lesioned marmosets, dopamine reuptake inhibitors have been demonstrated to reverse parkinsonian signs without evoking established dyskinesia. NS 2330 inhibits reuptake of dopamine, serotonin, and norepinephrine. We performed a proof‐of‐concept, randomized, double‐blind trial of NS 2330. Two hundred sixty‐one subjects with PD < 5 years and not receiving dopaminergic treatment were randomly assigned to daily treatment with NS 2330 at 0.25 mg, 0.5 mg, 1.0 mg, or placebo. Adjusted mean difference in total Unified Parkinson's Disease Rating Scale (UPDRS) scores from baseline to week 14 was −0.7 (P = 0.64) in the 0.25‐mg group, −1.3 (P = 0.41) in the 0.5‐mg group, and −1.7 (P = 0.27) in the 1.0‐mg group. The adjusted mean difference in total UPDRS score for the highest dose group (1.0 mg/day) was superior to placebo at week 6 (−3.1; P = 0.02), but this effect was not sustained. NS 2330 was generally well tolerated and the most commonly reported adverse events were constipation, insomnia, and dry mouth. Decreased body weight and elevated heart rate were common in the 1.0‐mg dosage group. At the dosages tested, NS 2330 did not provide significantly greater benefit than placebo. It is possible that inhibition of dopamine reuptake alone does not provide clinical benefit in early PD, adequate inhibition of dopamine reuptake was not achieved in this study, or countervailing physiologic mechanisms offset the potential benefit. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21258
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000808
- to stream Istex, to step Curation: 000808
- to stream Istex, to step Checkpoint: 001736
- to stream PubMed, to step Corpus: 002943
- to stream PubMed, to step Curation: 002943
- to stream PubMed, to step Checkpoint: 002599
- to stream Ncbi, to step Merge: 001996
- to stream Ncbi, to step Curation: 001996
- to stream Ncbi, to step Checkpoint: 001996
- to stream Main, to step Merge: 003B50
- to stream PascalFrancis, to step Corpus: 001779
- to stream PascalFrancis, to step Curation: 001542
- to stream PascalFrancis, to step Checkpoint: 001495
- to stream Main, to step Merge: 004085
- to stream Main, to step Curation: 002C28
- to stream Main, to step Exploration: 002C28
- to stream France, to step Extraction: 000322
Links to Exploration step
ISTEX:A58790C7A36893156A9C1384C48EF74D6D47BB21Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Salin, Laurence" sort="Salin, Laurence" uniqKey="Salin L" first="Laurence" last="Salin">Laurence Salin</name></author><author><name sortKey="Juhel, Nolwenn" sort="Juhel, Nolwenn" uniqKey="Juhel N" first="Nolwenn" last="Juhel">Nolwenn Juhel</name></author><author><name sortKey="Konyago, Victor L" sort="Konyago, Victor L" uniqKey="Konyago V" first="Victor L." last="Konyago">Victor L. Konyago</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A58790C7A36893156A9C1384C48EF74D6D47BB21</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21258</idno><idno type="url">https://api.istex.fr/document/A58790C7A36893156A9C1384C48EF74D6D47BB21/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000808</idno><idno type="wicri:Area/Istex/Curation">000808</idno><idno type="wicri:Area/Istex/Checkpoint">001736</idno><idno type="wicri:doubleKey">0885-3185:2007:Hauser R:randomized:trial:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17149725</idno><idno type="wicri:Area/PubMed/Corpus">002943</idno><idno type="wicri:Area/PubMed/Curation">002943</idno><idno type="wicri:Area/PubMed/Checkpoint">002599</idno><idno type="wicri:Area/Ncbi/Merge">001996</idno><idno type="wicri:Area/Ncbi/Curation">001996</idno><idno type="wicri:Area/Ncbi/Checkpoint">001996</idno><idno type="wicri:doubleKey">0885-3185:2007:Hauser R:randomized:trial:of</idno><idno type="wicri:Area/Main/Merge">003B50</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0181694</idno><idno type="wicri:Area/PascalFrancis/Corpus">001779</idno><idno type="wicri:Area/PascalFrancis/Curation">001542</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001495</idno><idno type="wicri:doubleKey">0885-3185:2007:Hauser R:randomized:trial:of</idno><idno type="wicri:Area/Main/Merge">004085</idno><idno type="wicri:Area/Main/Curation">002C28</idno><idno type="wicri:Area/Main/Exploration">002C28</idno><idno type="wicri:Area/France/Extraction">000322</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Salin, Laurence" sort="Salin, Laurence" uniqKey="Salin L" first="Laurence" last="Salin">Laurence Salin</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Boehringer Ingelheim France, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Juhel, Nolwenn" sort="Juhel, Nolwenn" uniqKey="Juhel N" first="Nolwenn" last="Juhel">Nolwenn Juhel</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Boehringer Ingelheim France, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Konyago, Victor L" sort="Konyago, Victor L" uniqKey="Konyago V" first="Victor L." last="Konyago">Victor L. Konyago</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-02-15">2007-02-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="359">359</biblScope><biblScope unit="page" to="365">365</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A58790C7A36893156A9C1384C48EF74D6D47BB21</idno><idno type="DOI">10.1002/mds.21258</idno><idno type="ArticleID">MDS21258</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bicyclo Compounds, Heterocyclic (therapeutic use)</term><term>Clinical trial</term><term>Dopamine</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>NS 2330</term><term>Nervous system diseases</term><term>Neurotransmitter Uptake Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Retrospective Studies</term><term>Reuptake inhibitor</term><term>Tesofensine</term><term>Treatment</term><term>clinical trial</term><term>dopamine reuptake inhibitor</term><term>dopamine transporter</term><term>monotherapy</term><term>tesofensine</term><term>treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bicyclo Compounds, Heterocyclic</term><term>Neurotransmitter Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term><term>Essai clinique</term><term>Inhibiteur recapture</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term><term>Tésofensine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). In MPTP (1‐methyl 4‐phenyl‐tetrahydropyridine 1,2,3,6)‐lesioned marmosets, dopamine reuptake inhibitors have been demonstrated to reverse parkinsonian signs without evoking established dyskinesia. NS 2330 inhibits reuptake of dopamine, serotonin, and norepinephrine. We performed a proof‐of‐concept, randomized, double‐blind trial of NS 2330. Two hundred sixty‐one subjects with PD < 5 years and not receiving dopaminergic treatment were randomly assigned to daily treatment with NS 2330 at 0.25 mg, 0.5 mg, 1.0 mg, or placebo. Adjusted mean difference in total Unified Parkinson's Disease Rating Scale (UPDRS) scores from baseline to week 14 was −0.7 (P = 0.64) in the 0.25‐mg group, −1.3 (P = 0.41) in the 0.5‐mg group, and −1.7 (P = 0.27) in the 1.0‐mg group. The adjusted mean difference in total UPDRS score for the highest dose group (1.0 mg/day) was superior to placebo at week 6 (−3.1; P = 0.02), but this effect was not sustained. NS 2330 was generally well tolerated and the most commonly reported adverse events were constipation, insomnia, and dry mouth. Decreased body weight and elevated heart rate were common in the 1.0‐mg dosage group. At the dosages tested, NS 2330 did not provide significantly greater benefit than placebo. It is possible that inhibition of dopamine reuptake alone does not provide clinical benefit in early PD, adequate inhibition of dopamine reuptake was not achieved in this study, or countervailing physiologic mechanisms offset the potential benefit. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>France</li><li>États-Unis</li></country><region><li>Connecticut</li><li>Floride</li></region><settlement><li>Paris</li></settlement></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></region><name sortKey="Konyago, Victor L" sort="Konyago, Victor L" uniqKey="Konyago V" first="Victor L." last="Konyago">Victor L. Konyago</name></country><country name="France"><noRegion><name sortKey="Salin, Laurence" sort="Salin, Laurence" uniqKey="Salin L" first="Laurence" last="Salin">Laurence Salin</name></noRegion><name sortKey="Juhel, Nolwenn" sort="Juhel, Nolwenn" uniqKey="Juhel N" first="Nolwenn" last="Juhel">Nolwenn Juhel</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000322 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000322 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:A58790C7A36893156A9C1384C48EF74D6D47BB21
|texte= Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |